EuroPCR: That's Interventional Medicine
EuroPCR 2013 will offer to the interventional community another unique opportunity to advance the burning questions we are facing.
Next month, much attention will again be devoted to the life-saving procedures we deliver day after day, night after night: primary PCI for STEMI and high-risk NSTEMI, TAVI for patients with high surgical risk, left main stenting in suitable lesion/patient subsets.
Other burning questions can already be identified:
- Is it time to consider expanding indications for TAVI to patients with intermediate surgical risk?
That’s Interventional Medicine. - What is the value of newer valve designs? Will these hold the promise of better outcomes by further reducing aortic regurgitation? How can we further reduce the risk of stroke? All roads lead to the heart: how to choose between access routes?
That’s Interventional Medicine. - What is the status of antiplatelet therapy: which drug should I use? For how long? For which stent?
That’s Interventional Medicine. - Sympathetic modulation by renal denervation: why, how and when should be involved in 2013, the indications and results for the longer term will have to be consolidated before we can sustain the dissemination of a myriad of devices and procedures.
That’s Interventional Medicine.
Is that all? It is not, by far.
We will address in-depth specific segments of our practice that continuously challenge our interventional skills.
- When and how to apply double stent techniques or dedicated stents for complex bifurcations with large side branches?
- You will not miss the opportunity to improve your expertise in radial interventions through direct and close interaction with pioneers in the field.
- Another highlight will be the joint session on CTO intervention in collaboration with our colleagues from CCT in Japan.
Did we mention about endovascular interventions in the peripheral circulation?
Don’t stay behind: join the team in the room Maillot and the endovascular village. See by yourself the new EuroPCR Board members, a new approach to the disease, a new multidisciplinary engagement from different specialists.
That’s Interventional Medicine.
These are the highlights so far. As the Course programme will continue to shape towards its final state, we will keep you informed about innovation sessions that will be discussing the latest trials and present the yearly harvest of innovative tools and devices at various levels of development, from the initial concept to the first-in-man evaluation, but … that is for later! As of now, be sure to make your plans in order to be able to participate.
At the end of 4 days of hard work, together, we will find answers and solutions to the burning questions, and return to our labs while fully informed and optimally skilled, in the best interest of each and every individual patient.
That’s Interventional Medicine.
Browse the interactive programme. Discover how to personalise your EuroPCR.
Access the final version of the scientific programme.
International participation
Over 11,000 active participants came to Paris last May.
See the representation from the worldwide EuroPCR community!
Please note that this course is not organised by the European Society of Cardiology. For any question, please visit EuroPCR website